Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 151

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 151
---
 Company’s board of directors determined to increase the number of shares available for issuance under the Company’s
employee stock option plan from 5,000,000 shares to 20,000,000 million shares, subject to shareholder approval. See Note 6.

:

The Common
Stock confers upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in the
distribution of dividends, if any, declared by the Company from legally available funds for the payment thereof, and rights to receive
a distribution of assets upon liquidation.

The Company
is authorized to issue 10,000,000 shares of $0.001 par value preferred shares. As of December 31, 2023, no shares of Preferred Stock were
outstanding.

| a. | In December 2020, the Company initially closed on a private                                                                           
 placement (the “2020 Private Placement”) of units of the Company ‘securities where each unit (a “Unit”                                
 and collectively the “Units”) is comprised of (i) two (2) shares of the Company’s Common Stock and (ii) one common                    
 stock purchase warrant to purchase an additional share of the Company’s Common Stock through December 9, 2023 at a per share exercise 
 price of $0.80 (the “2020 Private Placement Warrant”). The price per unit was $0.80. The Company raised aggregate gross proceeds      
 of $1,840 from the initial closing of the 2020 Private Placement and issued 4,600,000 Common stock and 2,300,000 warrants. On January 
 22, 2021 the Company received additional$ 500 in respect of the 2020 Private Placement and issued 1,250,000 Common stock and 625,000  
 Warrants with the same terms of 2020 Private Placement.                                                                               |

| b. | On March 15, 2021 the Company received additional $50 in respect of the 2020 Private Placement and issued 
 125,000 Common stock and 62,500 Warrants with the same terms of 2020 Private Placement.                   |

| c. | On April 19, 2021 the Company received additional $25 in respect of the 2020 Private Placement and issued 
 62,500 Common stock and 31,250 Warrants with the same terms of 2020 Private Placement.                    |

<div align='center'>F-44</div>

REVIUM RX